Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRAMADOL HCL

All products: not a benefit

Other products in the same Health Canada class (N02A) — coverage varies; not interchangeable

  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, Not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
  • Hydromorphone (Hydromorph Contin): general benefit, Not a benefit
  • Morphine (M-Eslon): general benefit, Not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, Not a benefit
  • Acetylsalicylic acid + oxycodone (Ratio-Oxycodan): general benefit, Not a benefit

4 more in the class list below

Jamp Tramadol HCl · DIN 02518759 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Tramadol HCl · DIN 02518759 Manufacturer: Jamp Pharma Corporation; listing date 2023-03-31 Health Canada: Marketed since 2023-02-08 · brand JAMP TRAMADOL HCL · ATC N02AX02 TRAMADOL · form Tablet · route Oral · ingredients TRAMADOL HYDROCHLORIDE 50 MG · company Jamp pharma corporation · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100805 · Verify on the e-Formulary ↗ (DIN 02518759)

Source record
DIN 02518759: Jamp Tramadol HCl Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280808287; group id 412; item number 1017; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6386; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02518759 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100805
Interchangeable products
Apo-Tramadol · DIN 02426153 · not recorded Auro-Tramadol · DIN 02479672 · not recorded Jamp Tramadol · DIN 02507005 · not recorded Mar-Tramadol · DIN 02480859 · not recorded Sandoz Tramadol · DIN 02493764 · not recorded Ultram · DIN 02349469 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02518759
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

TRAMADOL HCL & ACETAMINOPHEN

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TRIDURAL (tramadol hydrochloride extended-release tablets) is indicated for the management of moderate to moderately severe pain in adults who require treatment for several days or more. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 7.1.4 Geriatrics; 10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics). In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy (see 4.1 Dosing Considerations). https://pdf.hres.ca/dpd_pm/00083800.PDF PM date: MAR 9, 2026 Source product: TRIDURAL; DIN 02296381; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Jamp Tramadol HCl: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026